Pacritinib
Phase I/II Trial of Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms
More Information
- Trial Status
- Not yet accepting
- Trial Phase
- Phase 1/2
- Enrollment
- 160 patients (estimated)
- Sponsors
- National Cancer Institute (NCI)
- Tags
- CSF1R Inhibitor, IRAK 1 Inhibitor, JAK2 Inhibitor, Kinase Inhibitor, FLT3
- Trial Type
- Treatment
- Last Update
- 3 days ago
- SparkCures ID
- 1849
- NCT Identifier
- NCT06303193
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.